Published in Health Qual Life Outcomes on September 10, 2014
Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Qual Life Res (2016) 0.75
The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment. Pharmacoeconomics (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
The estimation of a preference-based measure of health from the SF-36. J Health Econ (2002) 14.18
A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ (2004) 4.42
The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol (2008) 3.14
Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes (2009) 2.05
Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics (2007) 1.94
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol (2014) 1.51
Health state utilities for metastatic breast cancer. Br J Cancer (2006) 1.50
Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ (2006) 1.40
Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol Assess (2012) 1.26
Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health (2011) 1.20
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes (2008) 1.19
Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer (2009) 1.09
Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer (2006) 1.03
Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics (2014) 1.01
Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health (2011) 0.93
Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. Value Health (2012) 0.90
A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation. Med Decis Making (2010) 0.89
Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ (2012) 0.87
Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice. Pharmacoeconomics (2011) 0.87
Quality-adjusted life expectancies in patients with rheumatoid arthritis--comparison of index scores from EQ-5D, 15D, and SF-6D. Value Health (2012) 0.79
A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis. Clin Exp Rheumatol (2011) 0.78
Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes (2011) 2.72
Improving the measurement of QALYs in dementia: developing patient- and carer-reported health state classification systems using Rasch analysis. Value Health (2011) 1.52
Estimating a preference-based index from the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM): valuation of CORE-6D. Med Decis Making (2012) 1.51
Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health (2013) 1.44
Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health (2009) 1.29
Mapping onto Eq-5 D for patients in poor health. Health Qual Life Outcomes (2010) 1.20
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics (2007) 1.05
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther (2011) 1.05
Developing preference-based health measures: using Rasch analysis to generate health state values. Qual Life Res (2010) 0.96
Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther (2008) 0.89
Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm. Value Health (2012) 0.88
The impact of adding an extra dimension to a preference-based measure. Soc Sci Med (2011) 0.86
Binary choice health state valuation and mode of administration: head-to-head comparison of online and CAPI. Value Health (2013) 0.86
Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. Eur J Health Econ (2011) 0.81
Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ (2009) 0.80
Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer. Value Health (2013) 0.80
Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol (2012) 0.80
Estimating the SF-6D value set for a population-based sample of Brazilians. Value Health (2011) 0.80
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol (2014) 0.79
The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy Behav (2012) 0.78
From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluation. Health Qual Life Outcomes (2014) 0.78
Common scale valuations across different preference-based measures: estimation using rank data. Med Decis Making (2013) 0.77
Do Portuguese and UK health state values differ across valuation methods? Qual Life Res (2011) 0.77
A Portuguese value set for the SF-6D. Value Health (2010) 0.76
Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ (2009) 0.76
A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. J Med Econ (2014) 0.75
Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL). Br J Haematol (2014) 0.75
Exploring the consistency of the SF-6D. Value Health (2013) 0.75